Sector Investors News and Insights

Teva Pharmaceutical Industries Limited

Insights on switching from Invega Sustenna to UZEDY for schizophrenia treatment are revealed by new data.

Teva Pharmaceuticals in the United States, a branch of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has revealed the unveiling of seven studies on its extended-release injection technology.

Insights on switching from Invega Sustenna to UZEDY for schizophrenia treatment are revealed by new data. Read More »

,
Scroll to Top

Subscribe to our Newsletter

Stay updated with the latests analysis and insights fromm etfsector.com

If you haven’t received your newsletter email, check your spam/junk folder and add us to your contacts to ensure delivery.